Apellis Announces Late-Breaking Presentation of Targeted C3 Therapy Pegcetacoplan in Patients with Geographic Atrophy (GA)

Source: Apellis Pharmaceuticals

Apellis Pharmaceuticals announced that a post hoc analysis of the phase 2 FILLY study investigating intravitreal pegcetacoplan (APL-2) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) has been accepted as a late-breaking oral presentation by EURETINA 2020 Virtual.

This new analysis of the FILLY study demonstrates that pegcetacoplan impacts the progression of nascent GA,1,2 the earlier stage of disease that precedes atrophy, in areas of the retina outside of GA lesions. The data are from a collaboration with the Doheny Image Reading Research Lab, and will be presented by SriniVas Sadda, MD, at the “Late Breaking & Reviews” oral session.

“We are excited that this post hoc analysis of the FILLY study was selected by EURETINA as a late-breaking presentation. These new data highlight the potential of targeting C3 with pegcetacoplan to transform the treatment of GA, a disease that leads to irreversible vision loss and has no approved treatments,” said Federico Grossi, MD, PhD, Chief Medical Officer of Apellis.

Featured Presentation
Impact of Pegcetacoplan on Progression of Nascent Atrophy in AMD, October 3, 5:05 p.m. CET.


Related Content